UBS Group’s Revance Therapeutics, Inc. RVNC Stock Holding History

UBS Group’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10,000	Closed	-$322K	–	9851
2023 Q1	$322K	Hold	10,000	–	–	﹤0.01%	5023
2022 Q4	$185K	Buy	+10,000	New	+$229K	﹤0.01%	5524
2020 Q1	–	Sell	-5,000	Closed	-$81K	–	8519
2019 Q4	$81K	Buy	+5,000	New	+$77.5K	﹤0.01%	6104

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

UBS Group's RVNC Position: Q1 2025 in Review

UBS Group sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 1,483,040 shares — an estimated $4.51M sold.

UBS Group first reported a position in RVNC in Q4 2014 and held it in 41 quarters. The position peaked at $4.51M in Q4 2024. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

UBS Group reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
UBS Group sold 1,483,040 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $4.51M.
UBS Group first reported a position in Revance Therapeutics, Inc. in Q4 2014 and held it in 41 quarters.
UBS Group's Revance Therapeutics, Inc. position peaked at $4.51M in Q4 2024.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on UBS Group's 13F filing for Q1 2025, filed 13 May 2025.